✦ LIBER ✦

Axitinib for renal cell carcinoma

✍ Scribed by Sonpavde, Guru; Hutson, Thomas E; Rini, Brian I

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Is axitinib the preferred second-line ag

✍ Bradford R. Hirsch; Daniel J. George 📂 Article 📅 2012 🏛 Frontline Medical Communications, Inc. 🌐 English ⚖ 83 KB

81 Updated results of the phase 3 AXIS t

✍ B. Escudier; B.I. Rini; T.E. Hutson; M. Gore; S. Oudard; J. Tarazi; B. Rosbrook; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 70 KB

3006 POSTER DISCUSSION Time to Deteriora

✍ D. Cella; B. Escudier; B. Rini; C. Chen; H. Bhattacharyya; J. Tarazi; B. Rosbroo 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 44 KB

Axitinib in Metastatic Renal Cell Carcin

✍ Kriti Mittal, Laura S. Wood, Brian I. Rini 📂 Article 📅 2012 🏛 Springer Healthcare Communications 🌐 English ⚖ 924 KB

Axitinib and sorafenib in second-line tr

✍ Jame Abraham 📂 Article 📅 2012 🏛 Frontline Medical Communications, Inc. 🌐 English ⚖ 85 KB

Maximizing clinical outcomes with axitin

✍ Laura S. Wood; Suzanne Gornell; Brian I. Rini 📂 Article 📅 2012 🏛 Frontline Medical Communications, Inc. 🌐 English ⚖ 296 KB